Skip to search formSkip to main content

Power mobility device, not coded by dme pdac or does not meet criteria

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, and early diagnosis and assessment may enhance… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2019
2019
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal malignancies. Given that macroautophagy… Expand
Is this relevant?
2019
2019
OBJECTIVE Pancreatic ductal adenocarcinoma (PDAC) is the most aggressive type of GI tumour, and it possesses deregulated cellular… Expand
Is this relevant?
2019
2019
The present study aimed to determine the clinical significance and potential molecular mechanisms of C‑C motif chemokine receptor… Expand
Is this relevant?
2019
2019
Pancreatic ductal adenocarcinoma (PDAC) is a destructive cancer with poor prognosis. Both novel therapeutic targets and… Expand
Is this relevant?
2018
2018
With a 5‑year survival rate of only 8%, pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer‑associated… Expand
  • table I
  • figure 1
  • figure 2
  • figure 3
  • table II
Is this relevant?
2015
2015
Mutated KRAS (KRAS*) is a fundamental driver in the majority of pancreatic ductal adenocarcinomas (PDAC). Using an inducible… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by poor survival despite current medical and surgical… Expand
Is this relevant?
2013
2013
2013
Pancreatic ductal adenocarcinoma (PDAC) remains a dismal disease with a poor prognosis and targeted therapies have failed in the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?